No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LUCD Lucid Diagnostics
- 0.910
- -0.020-2.18%
Close May 21 16:00 ET
- 0.910
- 0.000-0.02%
Post 18:52 ET
47.41MMarket Cap-721P/E (TTM)
0.940High0.900Low279.18KVolume0.920Open0.930Pre Close258.38KTurnover1.63%Turnover RatioLossP/E (Static)52.11MShares1.85052wk High-1.46P/B15.57MFloat Cap0.63052wk Low--Dividend TTM17.12MShs Float13.520Historical High--Div YieldTTM4.30%Amplitude0.630Historical Low0.925Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Buy Rating Affirmed for Lucid Diagnostics Amid Positive Financial and Clinical Milestones
Express News | Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $3 Price Target
Lucid Diagnostics (LUCD) Gets a Buy From Cantor Fitzgerald
Lucid Diagnostics: A Buy Rating on Operational Growth and Strategic Milestones
Lucid Diagnostics Insights: Performance and Outlook Update
Press Release: PAVmed Provides Business Update and First Quarter 2024 Financial Results
PAVmed Provides Business Update and First Quarter 2024 Financial Results PR Newswire NEW YORK, May 13, 2024 Lucid strengthens balance sheet and secures a July 17, 2024 MolDX pre-submission meeting
Comments
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago
PR Newswire· 2 mins ago
1
2
$Lucid Diagnostics(LUCD.US$
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
2
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
1
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test![]()
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg